Faculty Scholarship

2015

Serum Cotinine and Chronic Pain: NHANES
2003-2004
R Constance Wiener
West Virginia University, rwiener2@hsc.wvu.edu

Follow this and additional works at: https://researchrepository.wvu.edu/faculty_publications
Part of the Epidemiology Commons
Digital Commons Citation
Wiener, R Constance, "Serum Cotinine and Chronic Pain: NHANES 2003-2004" (2015). Faculty Scholarship. 887.
https://researchrepository.wvu.edu/faculty_publications/887

This Article is brought to you for free and open access by The Research Repository @ WVU. It has been accepted for inclusion in Faculty Scholarship
by an authorized administrator of The Research Repository @ WVU. For more information, please contact ian.harmon@mail.wvu.edu.

Research Article

iMedPub Journals
http://www.imedpub.com

Journal of Drug Abuse
2471-853X

2015
Vol. 1 No. 1:3

DOI: 10.21767/2471-853X.10003

Serum Cotinine and Chronic Pain:
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Abstract
Purpose: Tobacco smoke exposure continues to be the leading preventable risk
factor for many diseases and has the potential to be a risk factor for chronic pain.
The purpose of this study is to determine the relationship of chronic pain with
smoking, secondhand smoke exposure and non-smoking using serum cotinine
(and self-report of living with someone who smokes in the home) to identify the
tobacco exposure groups.
Methods: The National Health and Nutrition Examination Survey (NHANES) 20032004 was used for this study. Participants were queried about pain duration
and had serum cotinine levels determined during the course of the NHANES
examination/survey. Participants, ages 20 years and above, with complete data on
chronic pain, cotinine level, sex, race/ethnicity, and responses concerning living
with someone who smoked in the home were included in the study (n=4429).
Results: The adjusted odds ratio of tobacco smoke exposure on chronic pain was
1.67 (95% CI: 1.08, 2.59; p=0.0220) for participants with a serum cotinine level >10
ng/mg (smokers) as compared with individuals who had a non-detectable serum
cotinine level. For individuals with a serum cotinine level >0.011 ng/mg to 10 ng/
mg who identified as living with someone who smoked in the home, the adjusted
odds ratio was 0.88 (95% CI: 0.47, 1.65; p=0.6785) as compared with individuals
who had a non-detectable serum cotinine level.
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Introduction
Exposure to tobacco smoke is a significant public health issue
as there are approximately 4700 chemicals present in tobacco
smoke of which 250 are known to be toxic or carcinogenic [1].
Most notably, tobacco smoke has nicotine, tar, nitric oxide,
carbon monoxide, aromatic amines [2], formaldehyde, benzene,
hydrogen cyanide, acetone, and Polonium-210 [3]. Although the
prevalence of smoking cigarettes has decreased since the release
of the U.S. Surgeon General's Report on Smoking and Health in
1966, there remains approximately 13.4% of the U.S. population
who smoke daily and 5.4% who smoke some days [4]. Smoking
is associated with approximately 480,000 deaths annually in the
U.S., including 42,000 deaths from secondhand smoke (SHS)

exposure [5]. The cost of smoking in the U.S. is $300 billion per
year ($170 billion in medical care, $156 billion in lost productivity
due to premature death) [5]. Even limited or light smoking
has health risks. Tobacco usage has been associated with lung
diseases, cancers, cardiovascular disease, stroke, mood disorders,
rheumatoid arthritis, headache, and fibromyalgia among other
diseases and conditions [6,7]. Smoking also has the potential to
be a risk factor for chronic pain [6,7].
The conceptual framework of chronic pain is that it is a situation
in which a person has an ongoing negative subjective experience
with many biopsychosocial factors and interactions (any of which
may have clinical significance) [8]. Researchers have varying
definitions of the cut-point at which pain is defined as chronic.
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Typical cut-points are 3 months, 6 months, and 12 months pain
duration. In a recent U.S. study, the prevalence of chronic pain,
defined as lasting at least 6 months, was 30.7% [9]. Researchers
using 2008 Medical Expenditure Panel Survey data estimated
100 million adults in the U.S. had chronic pain and the total costs
were from $560 to $635 billion in 2010 dollars [10].
The purpose of this study is to determine the relationship
of chronic pain with smoking, SHS exposure, tobacco smoke
exposure of unknown source, and non-smoking using serum
cotinine (and self-report of living with or not living with someone
who smokes in the home) to identify the tobacco exposure
groups. The theoretical framework is the biopsychosocial model
of health as explained by Ditre, et al. [6] in which, for smoking and
chronic pain, there is an interplay or positive feedback loop with
greater pain, increased smoking, and maintenance of the tobacco
addiction through biomedical, behavioral, cognitive/affective, and
physiological/sensory phenomena in social context. The research
hypothesis is that smoking is more strongly associated with
chronic pain than non-smoking as measured by serum cotinine
level.

Methods
Participants
Data from the National Health and Nutrition Examination Survey
(NHANES) 2003-2004 was used for this study. Researchers from
the Centers for Disease Control and Prevention conduct surveys
of non-institutionalized U.S. civilians using a multistage, stratified
probability design. The study design is representative of the U.S.
population. All participants provide verbal and written consent.
Details of the sampling strategy are available from the NHANES
website: http://www.cdc.gov/nchs/nhanes.htm.
This study is a cross-sectional, secondary data analysis of the
publicly available, de-identified NHANES 2003-2004 data. The
sample for the study of chronic pain and smoking was limited to
participants who had no missing data concerning chronic pain,
cotinine level, sex, age, race/ethnicity, and responses concerning
living with someone who smoked in the home. Participants were
also limited to the ages of 20 years and above as the NHANES
questions concerning pain were presented to participants who
were at least age 20 years. The final sample size was 4429
participants.

Outcome variable: Chronic pain
Chronic pain was the outcome variable. It was derived from 2
NHANES questions. The first question asked of participants was
if they had pain that lasted more than 24 hours in the previous
month. The second question asked of participants who endorsed
the first question, was the length of time that the pain was
experienced. Options for the second question were: less than a
month; one to less than 3 months; 3 months to less than a year;
and greater than a year. For this study, pain lasting at least 3
months was defined as chronic pain, based on the definition of
the American College of Rheumatology and previous research
[11,12].
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Key independent variable: Tobacco smoke exposure
(Serum cotinine levels)
Serum cotinine level was the key independent variable. Based
upon previous definitions using serum cotinine levels [2,13],
a participant was defined as a smoker if he or she had a serum
cotinine level above10 ng/mg. A participant was defined as
having SHS exposure if he or she self-identified as living in a home
in which someone smoked and had a cotinine level greater than
0.011 ng/mg but less than or equal to 10 ng/mg. A participant was
defined as having tobacco smoke exposure of unknown source if
he or she indicated he or she did not live in a home in which
someone smoked and had a cotinine level greater than 0.011
ng/mg but less than or equal to 10 ng/mg. Individuals with nondetectable serum cotinine levels were defined as non-smokers.

Other important variables
Variables considered in the study were selected to address the
biopsychosocial theoretical framework: age (20 years to less than
45 years, 45 years to less than 60 years, and 60 years and above);
sex (male, and female); race/ethnicity (Non-Hispanic white, NonHispanic black, Mexican American, and other); income to poverty
ratio (less than 1.25, 1.25 to less than 2.00, 2.00 to less than 4.00,
and 4.00 and above); education (less than High School, High
School graduate, more than High School); marital status (married
and not married); body mass index (less than 25, 25 to less than
30, 30 and above); insurance (yes and no); exercise (yes and no);
and alcohol use (heavy, moderate, and none). Heavy alcohol use
was defined as an average of more than 2 drinks a day on the
days in which the participant drank, and moderate alcohol use
was defined as an average of 1 or 2 drinks a day on the days in
which the participant drank.

Statistical analysis
The data were analyzed with SAS 9.3® (Cary, NC). Variable
frequencies were determined for the characteristics of the
study participants. Bivariate associations of the serum cotinine
levels and other important variables with chronic pain were
conducted with Chi square analyses. Significant variables in the
bivariate analyses were included in the logistic regression model
development for the association of serum cotinine levels on
chronic pain. Due to the complex study design of the NHANES
data, considerations were made for the selected eligible sample,
masked variance pseudo-stratum (SDMVSTRA), masked variance
pseudo-primary sampling unit (SDMVPSU) and full sample 2
year Mobile Examination Center exam weight (WTMEC2YR) in
the bivariate analyses and logistic regressions. The alpha for the
analysis was established, a priori, as 0.05.

Results
The sample had 17.9% (n=733) of participants reporting chronic
pain and 29.6% (n=1172) of participants having serum cotinine
levels >10 ng/mg. There were 51.6% (n=2284) females; 49.6%
(n=1916) ages 20-45 years, and 55.1% (n=2022) who had more
than a high school education. Most of the participants were nonHispanic white (72.5%; n=2369); insured (82.2%; n=3576); and
married (64.4%; n=2688). Details of the study characteristics are
presented in Table 1.
This article is available in: http://drugabuse.imedpub.com/archive.php
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Table 1 Sample characteristics, NHANES 2003-04.

Sample
Chronic Pain >= 3 mo
Yes
No
Serum Cotinine
>10 ng/mg (Smoker)
>0.011 to 10 ng/mg (SHS)
>.011 to 10 ng/mg1
Non-detectable
Sex
Male
Female
Age groups in years
20 to less than 45
45 to less than 60
60 and above
Race/ethnicity
NHW
NHB
Mexican Am
Other
Family income to poverty ratio
0 to less than 1.25
1.25 to less than 2.00
2.00 to less than 4.00
4.00 and above
Insurance
Yes
No
Education
Less than high school
High school graduate
More than high school
Marital Status
Married
Not married
Body mass index
Less than 25
25 to less than 30
30 and above
Exercise
Yes
No
Alcohol
Heavy use
Moderate use
Non-drinker

N
4429

Weighted Frequency

Weighted column % (SE)

733
3701

34,646,810
159,247,675

17.9 (1.3)
82.1 (1.3)

1172
202
2213
837

57,424,400
9,072,581
96,018,432
31,379,072

29.6 (1.7)
4.7 (0.5)
49.5 (1.4)
16.2 (2.0)

2145
2284

93,889,884
100,004,601

48.4 (0.7)
51.6 (0.7)

1916
882
1631

96,183,603
5,378,911
43,929,971

49.6 (1.6)
27.7 (1.3)
22.7 (1.0)

2369
847
887
326

16,267,413
20,925,464
14,925,350
17,411,975

72.5 (3.3)
10.8 (1.7)
7.7 (2.0)
9.0 (1.0)

1144
786
1185
1104

34,797,004
27,762,464
57,514,789
64,793,554

18.8 (1.6)
15.0 (0.7)
31.1 (1.3)
35.0 (2.1)

3576
851

159,272,926
34,474,920

82.2 (0.9)
17.8 (0.9)

1290
1111
2022

35,006,250
51,972,076
106,793,926

18.1 (0.7)
26.8 (1.1)
55.1 (1.3)

2688
1739

124,734,732
68,891,444

64.4 (1.3)
35.6 (1.3)

1361
1553
1429

63,457,655
66,318,721
61,149,655

33.2 (1.0)
34.7 (1.1)
32.0 (1.2)

2267
2161

112,186,435
81,678,646

57.8 (1.1)
42.1 (1.1)

942
1360
1274

46,058,168
65,900,422
50,225,392

28.4 (1.7)
40.6 (1.8)
31.0 (2.2)

N=Number; SE=Standard Error; NHW=Non-Hispanic White; NHB=Non-Hispanic Black; Am=American
SHS=Second Hand Smoke Exposure
1
tobacco smoke exposure of unknown source
© Under License of Creative Commons Attribution 3.0 License
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Table 2 Bivariate relationship of chronic pain with variables of interest, NHANES 2003-04.
Chronic Pain
Serum Cotinine
>10 ng/mg (Smoker)
>0.011 ng/mg (SHS)
>0.011 ng/mg to 0 ng/mg1
Non-detectable
Sex
Male
Female
Age groups in years
20 to less than 45
45 to less than 60
60 and above
Race/ethnicity
NHW
NHB
Mexican Am
Other
Family income to poverty ratio
0 to less than 1.25
1.25 to less than 2.00
2.00 to less than 4.00
4.00 and above
Insurance
Yes
No
Education
Less than high school
High school graduate
More than high school
Marital Status
married
not married
Body mass index
Less than 25
25 to less than 30
30 and above
Exercise
Yes
No
Alcohol
Heavy use
Moderate use
Non-drinker

N

Yes Weighted row %

N

No Weighted row %

252
35
324
117

23.9
16.4
15.0
16.0

920
172
1889
720

76.1
83.5
85.0
84.0

p-value
<.0001

0.0317
304
424

15.4
20.2

1841
1860

84.6
79.8

260
185
283

14.4
22.7
19.6

1656
697
1348

85.6
77.3
80.4

466
117
97
48

19.9
14.1
9.5
13.5

1903
730
790
278

80.1
85.9
90.5
86.5

222
129
196
150

22.0
18.8
19.7
14.0

922
657
989
954

78.0
81.2
80.3
86.0

594
133

18.2
16.3

2982
718

81.8
83.7

220
197
311

19.8
20.6
15.9

1070
914
1711

80.2
79.4
84.1

442
286

18.4
16.9

2264
1453

81.6
83.1

207
237
268

16.6
17.6
19.5

1154
1316
1161

83.4
82.4
80.5

332
396

15.5
21.1

1935
1765

84.4
78.9

137
209
220

16.4
17.1
18.0

805
1151
1054

83.6
82.9
82.0

<0.0001

0.0039

0.1995

0.3966

0.2599

<0.0001

0.7986

N=Number; NHW= Non-Hispanic White; NHB= Non-Hispanic Black; Am=American
SHS=Secondhand Smoke Exposure
1
tobacco smoke exposure of unknown source

The results of the bivariate relationships with chronic pain are
presented in Table 2. The key variable, tobacco smoke exposure
(serum cotinine level), was significantly associated with chronic
pain (p<0.0001). Other significant variables were sex, age, race/
ethnicity, family income to poverty ratio, education, and exercise.
Marital status, body mass index, and alcohol use failed to reach
significance.

4

The logistic regression models are presented in Table 3. The
unadjusted odds ratio of tobacco smoke exposure (serum cotinine
level) on chronic pain was 1.65 (95% CI: 1.18, 2.30; p=0.0032) for
participants with a serum cotinine level >10 ng/mg (smokers)
as compared with individuals who had a non-detectable serum
cotinine level. For individuals with a serum cotinine level greater
thand.011 ng/mg but less than or equal to 10 ng/mg who
This article is available in: http://drugabuse.imedpub.com/archive.php
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Table 3 Logistic regression on chronic pain, NHANES 2003-04 by Serum Cotinine level.
Serum Cotinine level
>10 ng/mg (Smoker)
>0.011 ng/mg to 10 ng/mg (SHS
>0.011 ng/mg to 10 ng/mg1
Non-detectable
Serum Cotinine level
>10 ng/mg (Smoker)
>0.011 ng/mg to 10 ng/mg (SHS)
>0.011 ng/mg to 10 ng/mg1
Non-detectable
Sex
Male
Female
Age groups
20 to less than 45
45 to less than 60
60 and above
Race/ethnicity
NHB
Mexican Am
Other
NHW
Family income to poverty
0 to <1.25
1.25 to <2.00
2.00 to <4.00
4.00 and above
Education
Less than High School
High School Graduate
More than High School
Exercise
No
Yes

Unadjusted Odds Ratios (95%CI) 2001-2002

p-value

1.65 (1.18, 2.30)
1.04 (0.63, 1.69)
0.93 (0.71, 1.23)
reference
Adjusted Odds Ratios (95% CI)

0.0032
0.8910
0.6226

1.67 (1.08, 2.59)
0.88 (0.47, 1.65
1.01 (0.70, 1.46)
reference

0.0220
0.6785
0.9624
0.0463

0.73 (0.53, 1.00)
reference group
reference group
1.71 (1.31, 2.24)
1.35 (0.98, 1.85)

0.0001
0.0639

1.86 (1.38, 2.50)
1.52 (1.06, 2.17)
0.65 (0.39, 1.07)
reference group

<0.0001
0.9216
0.0886

1.86 (1.38, 2.50)
1.52 (1.06, 2.17)
1.50 (1.02, 2.20)
reference group

<0.0001
0.9216
0.0399

1.20 (0.93, 1.56)
1.16 (0.89, 1.51)
reference group

0.1706
0.2701

1.34 (1.08, 1.66)
reference group

0.0075

Abbreviations: CI: Confidence Interval; <- less than; NHB: Non-Hispanic Black; NHW: Non-Hispanic White; Am: American; SHS: Second Hand Smoke
Exposure.
1
tobacco smoke exposure of unknown source

identified as living with someone who smoked in the home, the
unadjusted odds ratio was 1.04 (95% CI: 0.63, 1.69; p=0.8910)
as compared with individuals who had a non-detectable serum
cotinine level. For individuals who reported that they did not live
with someone who smoked in the home and who had a serum
cotinine level greater than .011ng/mg but less than or equal to
10 ng/mg, the unadjusted odds ratio was 0.93 (95% CI: 0.71,
1.23; p=0.6226) as compared with individuals who had a nondetectable serum cotinine level.

10 ng/mg who identified as living with someone who smoked
in the home, the adjusted odds ratio was 0.88 (95% CI: 0.47,
1.65; p=0.6785) as compared with individuals who had a nondetectable serum cotinine level. For individuals who reported
that they did not live with someone who smoked in the home
and who had a serum cotinine level greater than.011 ng/mg but
less than or equal to 10 ng/mg, the adjusted odds ratio was 1.01
(95% CI: 0.70, 1.46; p=0.9624) as compared with individuals who
had a non-detectable serum cotinine level.

The adjusted odds ratio of tobacco smoke exposure (serum
cotinine level) on chronic pain was 1.67 (95% CI: 1.08, 2.59;
p=0.0220) for participants with a serum cotinine level >10 ng/
mg (smokers) as compared with individuals who had a nondetectable serum cotinine level. For individuals with a serum
cotinine level greater than.011 ng/mg but less than or equal to

Discussion

© Under License of Creative Commons Attribution 3.0 License

Research associated with nationally representative data
concerning chronic pain is limited. The purpose of this study was
to determine the relationship of chronic pain with smoking, SHS
exposure and non-smoking using serum cotinine (and self-report
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of living with someone who smokes in the home) to identify
the tobacco exposure groups. There were 17.9% of participants
endorsing having chronic pain lasting 3 or more months. There
were 29.6% of participants having serum cotinine levels greater
than 10 ng/mg. The adjusted odds ratio for smokers as compared
with non-smokers on chronic pain was 1.65 (95% CI: 1.18, 2.30;
p=0.0032). Results did not reach significance for individuals with
cotinine levels greater than.011 ng/mg but less than or equal to
10 ng/mg for chronic pain as compared with non-smokers. This
study adds to the literature results indicating smoking, as defined
with cotinine levels, is a risk factor for chronic pain.

Other studies
•

Similar results for the association of chronic pain and
tobacco smoke exposure were reported concerning a
rural population in which current smoking was associated
with chronic musculoskeletal pain (odds ratio 1.60; 95%
CI: 1.04, 2.46) and chronic back pain (odds ratio 1.58; 95%
CI: 1.13, 2.20) [13].

•

In a U.S. nationally representative study, researchers
found self-reported chronic pain and nicotine dependence
(diagnosed using the World Health Organization
Composite International Diagnostic Interview for trained
non-clinicians) to be associated. Participants who
endorsed current chronic neck or back pain were 2.30
(95% CI: 1.71, 3.11) times more likely to have current
nicotine dependence than participants without current
chronic neck or back pain [14].

•

•

In a large, representative sample in Canada in which
participants were asked about current cigarette use and
pain lasting 6 months or longer, participants who had
chronic back pain or arthritis were 1.54 (95% CI: 1.44,
1.65) times more likely to be daily cigarette smokers [15].
The results were adjusted for sociodemographic variables,
mood disorders, and anxiety [15].
In a large survey conducted in Britain, smokers had higher
risk for regional pain lasting 24 hours or more in the past
12 months than non-smokers (prevalence ratio 1.3, 95%
CI: 1.2, 1.4 for low back pain) [15,16].

Biological plausibility
From the late 1970’s, there was research on the effect of smoking
on pain in which nicotine was shown to release endogenous
opiates that relieve pain; additionally, dysphoric states such as
pain were also determined to be cues to smoke by providing the
situation (discriminative stimulus) for smoking reinforcement with

6
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beta-endorphin release [17]. Much of the research involved acute
pain (cold water, pressure, etc.) [17]. Nicotine activates nicotinic
acetylcholine receptors (nAChRs) throughout the central nervous
system to release dopamine, noradrenaline, acetylcholine,
glutamate and GABA [18]. Endogenous enkephalins and betaendorphins have roles in the rewarding effects of nicotine [18]. It
is therefore biologically plausible that chronic pain is temporarily
relieved by smoking, and the addiction cycle is strengthened in a
feedback loop.

Strengths and limitations
The study does have limitations. It is a cross-sectional study, and by
nature does not imply causality or temporality. Misclassification
of people exposed to SHS was possible since the definition was
dependent upon correct self-report of living with someone
who smoked. Misclassification is also possible in that the blood
sample may have been taken on a day in which a smoker had
not smoked for several days. (The half-life of plasma cotinine is
15-20 hours) [19]. Additionally, the cut-point for cotinine is not
firmly established in the literature. Researchers from Britain
have suggested a cut-point of 12ng/ml as an overall cut-point for
salivary cotinine levels [20].
A study strength is the use of the large representative NHANES
sample which was publicly available from the CDC. The data
collection, verification and representative study design of the
original NHANES 2003-2004 also are strengths for this study.
Additionally, cotinine, a biomarker for tobacco smoke exposure,
was used to identify smokers. Its use has the potential to correctly
identify individuals who smoke avoiding the social desirability
bias that may be associated with a self-report. The large national
nature of the study increases its potential for generalizability.

Conclusion
Chronic pain is a complex situation with many factors affecting it.
Similarly smoking is a complex addiction. The interplay of chronic
pain and smoking were significant in this study. Additional
research is needed to understand the relationship more fully.
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